
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
Table of Contents
about 23 years ago
The Outsiderabout 23 years ago
PE's annual Media Spend Trendsabout 23 years ago
A New Deal with Managed Careabout 23 years ago
Matters of (Re)Importabout 23 years ago
Show Us the Value




